DailyIQ
Last updatedjust now

BAX·Baxter International Inc.

$24.82
-0.07 (-0.28%)
After Hours
High
$25.04
Open
$24.86
Market Cap
12.86B
52W High
$30.00
Low
$24.58
P. Close
$24.82
P/E
-
52W Low
$15.73
Fwd P/E
12.20
DailyIQ Est.
$27.47
Inst. Ownership
52.4%
Short Interest
4.74%
Days to Cover
3.0
Div. Yield
0.16%
Next Ex-Div
~Nov 27
Technical Score (1D)
49
NEUTRAL
News Sentiment
37
BEARISH
On Oct 13, Baxter International announced that it would report its third‑quarter earnings later in the month, with analysts forecasting a sharp double‑digit year‑over‑year drop in earnings. The forecast reflected a significant contraction in revenue and profitability for the company. The guidance indicated a material negative impact on the company’s financial outlook. Analysts highlighted that the expected decline could influence future investor sentiment. The company’s announcement and the accompanying analyst predictions were reported on Oct 13.
LOW TARGET
$20 -19.4%
2 analysts
MEAN TARGET
$28 +12.6%
15 analysts
HIGH TARGET
$40 +61.3%
4 analysts
PRICE RANGE
$20.00 - $40.00
SB / B / H / S / SS
1/4/14/1/1
DAILYIQ EST.
$27.47 (+10.8%)
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NYQ
Country
United States
Website
Symbol
BAX
Description
Baxter International Inc. is a global healthcare company specializing in a diverse range of medical products and therapies. Its core offerings include sterile intravenous solutions, infusion systems, and essential pharmaceuticals, serving critical needs in hospitals and various healthcare settings. Baxter's value proposition centers on providing life-sustaining and life-improving products, encompassing surgical tools, patient monitoring technologies, and respiratory care devices. The company's comprehensive product portfolio is distributed through a multi-channel approach, leveraging direct sales, distributors, and strategic partnerships. Operating internationally, Baxter's products are utilized across a broad spectrum of healthcare environments, making it a significant player in the global medical products market.
Bought (1Y)
0 shares
$0
Sold (1Y)
57,598 shares
$1.5M
Foster JuliePresident, Front Line Care
Tax Withholding2,098 shares2026-09-02
Hider Andrew P.President and CEO
Tax Withholding54,276 shares2026-09-02
Teaff JamesPresident, CCS
Tax Withholding750 shares2026-09-01
Teaff JamesPresident, CCS
Tax Withholding321 shares2026-06-02
Wallace Steven P.President, Adv. Surgery
Tax Withholding153 shares2026-06-02
54/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✕Negative net margin
✓Positive operating cash flow
Gross Margin
30.1%
Net Margin
-8.5%
Revenue CAGR
0.0%
Current Ratio
2.31x
Debt / Equity
1.54x
Return on Equity
-15.6%
Earnings Summary
Baxter International Inc. (BAX) is a global healthcare company that supplies sterile intravenous solutions, infusion systems, and essential pharmaceuticals, operating within the medical instruments and supplies industry. In Q4 2024, Baxter reported EPS of $0.58 versus an estimate of $0.529, and revenue of $2.753 billion, exceeding the $2.705 billion estimate, marking a strong quarter. Q1 2025 saw EPS of $0.55 against an estimate of $0.483, with revenue of $2.625 billion, again beating forecasts; however, Q2 2025 EPS fell to $0.54 below the $0.610 estimate, while revenue of $2.810 billion surpassed the $2.770 billion estimate. Q3 2025 EPS rose to $0.69 versus an estimate of $0.598, and revenue of $2.835 billion exceeded the $2.835 billion estimate, indicating a rebound. Q4 2025 EPS of $0.44 beat the $0.328 estimate, and revenue of $2.974 billion surpassed the $2.605 billion estimate, reinforcing a pattern of revenue growth despite occasional EPS misses. Historically, Baxter has maintained YoY revenue growth of 5–7% over the past four quarters, with EPS growth fluctuating but generally meeting or exceeding analyst expectations in three of the last four quarters. Recent news reports from October 2024 show Barclays downgrading the stock to underweight with a $20 target, while Zacks and Citigroup have issued mixed coverage, reflecting concerns about valuation and short‑term earnings pressure.

EPS

EstBeatMiss
$0.25$0.38$0.50$0.62$0.75Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.52 - -
Q2'26$0.37$0.56+52.2%
Q1'26$0.31$0.36+15.7%
Q4'25$0.33$0.44+34.0%
Q3'25$0.60$0.69+15.4%
Q2'25$0.61$0.54-11.5%

Revenue

EstBeatMiss
$2.5B$2.7B$2.8B$2.9B$3.0BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.9B - -
Q2'26$2.8B$3.0B+4.9%
Q1'26$2.6B$2.7B+2.1%
Q4'25$2.6B$3.0B+14.2%
Q3'25 - $2.8B -
Q2'25 - $2.8B -

Market Data

BAX Stock Snapshot

NEUTRAL49/100
$24.80−$0.02 (0.1%)
Market cap
12.86B
Day range
$24.58 – $25.04
News sentiment
37/100 · Bearish
Analyst target
$27.92 (+12.6%)
Consensus
Hold · 21 analysts
52-week range+57.7% off low · -17.3% from high
$15.73$30.00
Price $24.80 DailyIQ Est. $27.47

BAX is in a holding pattern - neither trend nor momentum has taken control. In Healthcare, names this size usually take direction from sector flows before company-level news.

Reverse DCF

What growth is priced into BAX?

RICH

At today's price, Baxter International Inc. needs to grow free cash flow about 3.8% a year for the next 10 years to justify its valuation at a 6.85% cost of capital. Over its actual history it has compounded free cash flow at -6.4% a year, so the market is asking for 10.2 percentage points above its own delivered rate. On that basis BAX looks priced above what its own growth record supports.

Implied FCF growth
3.8%
Historical FCF CAGR
-6.4%
Growth gap
+10.2 pts
Verdict
RICH
Discount rate (WACC)
6.85%
Beta
0.93

Behaviour On Record

What BAX's own history says about today's numbers

Realized volatility (21d)
23.5% 56th pct
Below its peak
-73.6%
vs 200-day average
+18.8%
Up days (1y)
49%

Baxter International Inc. is currently running 23.5% annualised volatility over the last 21 sessions. Measured against BAX's own 13 years of daily returns rather than a market-wide average, that is the 56th percentile — close to its own typical level, against a typical reading of 22.2%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BAX is trading -73.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -22.0%, and the deepest was -52.1% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +18.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 97th percentile — a wider gap than this stock usually carries. Over the past year BAX closed higher on 49% of sessions, and it is currently 5 sessions into a rising streak.

On October specifically: over 14 years of records, BAX finished the month higher 4 of 14 times, with a median return of -2.5% and an average of -4.1%. Its strongest month historically has been April at +2.3% on average, its weakest October at -4.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BAX has opened more than 2% away from the prior close in 93 of 3,268 sessions (2.8% of the time), with the largest gaps running +5.4% and -5.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, BAX moved an average of 2.0% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.4% and a largest of +4.5%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against BAX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BAX's sector?

Baxter International Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for BAX?

CallsPuts

For Baxter International Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.45), with at-the-money implied volatility around 66.0%. The options market is pricing roughly a ±5.1% move by that expiry — a range of about $23.11–$25.59.

Put/call ratio (2026-10-16)
0.45
ATM implied volatility
66.0%
Total open interest
4,697
Expected move by 2026-10-16
±5.1% ($23.11–$25.59)

Analyst Rating Changes

Are analysts turning bullish or bearish on BAX?

Barclays most recently initiated coverage on Baxter International Inc. to Underweight on Oct 7, 2026 with a price target of $20. Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
Barclays — Underweight
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Oct 7, 2026BarclaysInitiatedUnderweight$20
Oct 5, 2026CitigroupMaintainedNeutral$28 → $27
Jul 31, 2026TD CowenMaintainedHold$24 → $29
Jul 31, 2026Wells FargoMaintainedEqual-Weight$19 → $23
Jul 31, 2026StifelMaintainedHold$24 → $28
Jul 31, 2026CitigroupUpgradeSell → Neutral$17 → $28
Jul 28, 2026UBSMaintainedNeutral$19 → $25
Jul 28, 2026StifelMaintainedHold$19 → $24
Jul 27, 2026TD CowenMaintainedHold$20 → $24
Jul 15, 2026Goldman SachsMaintainedNeutral$19 → $21
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$22 → $24
May 28, 2026CitigroupDowngradeNeutral → Sell$19 → $17

Peers & ETF holders

BAX peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

37/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Baxter announced that its quarterly earnings will be released on the scheduled date, with no additional financial details disclosed in the preview. The announcement serves as a routine update for investors awaiting the company’s performance metrics. No immediate impact on the company’s outlook was indicated.
What did this article say?
Baxter International reported that the transition to its new Vantive platform is complicating efforts to recover margins. The company’s management highlighted increased integration costs and operational disruptions as key obstacles. Analysts noted that these challenges could delay the company’s return to previous profitability levels, potentially impacting investor expectations. The situation underscores the broader risk of technology upgrades affecting cost structures in the medical device sector.
What did this article say?
Baxter International’s stock, trading near $24, is considered undervalued by analysts who highlight a 24.9% year‑to‑date gain amid a 66.3% decline over five years. A discounted cash flow model suggests the company’s future cash generation exceeds current market expectations. The valuation gap is driven by Baxter’s ability to convert its installed base into recurring revenue, positioning it for potential upside. The analysis underscores a positive outlook for the company’s long‑term financial health.
What did this article say?
Barclays announced it would begin coverage of Baxter International, assigning an underweight rating to the company. The bank cited concerns over Baxter’s competitive positioning and potential margin pressures in the medical device sector. The initiation signals a downgrade relative to the market consensus and may influence investor sentiment toward the stock. No immediate earnings or product announcements were disclosed in the statement. The coverage change reflects Barclays’ assessment of Baxter’s near‑term valuation risks.
What did this article say?
Baxter International Inc. (BAX) scheduled a conference call to discuss its third‑quarter 2026 financial results, to be held on October 29, 2026. The call will be webcast and accessible through Baxter’s website. Participants can pre‑register via the provided link. No financial guidance or performance updates were disclosed in the announcement. The event is a routine earnings call with no immediate impact on the company’s outlook.
What did this article say?
Evercore ISI lifted its price target for Baxter International (BAX) from $24 to $32, reflecting a more optimistic view of the company’s prospects. The upgrade follows a recent consensus rating of hold and an average target of $26.82 among analysts. The move signals confidence in Baxter’s earnings potential and product pipeline, suggesting a positive outlook for the stock. This adjustment may influence investor sentiment and trading activity in the near term.
What did this article say?
Barclays announced new coverage of Baxter International (BAX) with an underweight rating and a $20 price target. The bank noted that the current average rating across analysts is hold, with a mean target of $27.60. The downgrade reflects concerns about BAX’s valuation relative to peers and potential earnings pressure. The move signals a negative outlook for the company’s short‑term performance.
What did this article say?
Zacks analysts identified Baxter International (BAX) as a compelling value investment, citing its strong Zacks Rank #2 (Buy) and high Value grade. The firm highlighted BAX’s favorable earnings estimates and recent positive revisions, suggesting potential upside for investors. Analysts noted that BAX’s current share price appears undervalued relative to its fundamentals, positioning it as a top pick for value-oriented portfolios. The recommendation is based on quantitative metrics rather than speculative hype, underscoring a data‑driven endorsement.
What did this article say?
Baxter International (BAX) saw its full‑year earnings estimate rise 6.5% in the last quarter, reflecting a shift in analyst sentiment toward a more positive outlook. The company holds a Zacks Rank of #2 (Buy), placing it among the top performers in the medical sector. This upgrade suggests that BAX is expected to outperform peers over the next one to three months, though the move is not considered transformative.
What did this article say?
Citigroup reduced its price target for Baxter International from $28 to $27 while keeping a neutral rating. The adjustment reflects a modest reassessment of the company’s near‑term earnings outlook. The change does not alter the overall hold consensus among analysts. Investors may view the move as a slight headwind but not a material shift in expectations.

Technical Analysis

Real-time indicators across multiple timeframes

49
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $5.60B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy81,842,10515.91%$1.74B2026-08-07
Vanguard Group Inc▲ Buy62,635,13612.17%$1.20B2026-01-29
FMR LLC (Fidelity)▲ Buy53,913,83110.48%$1.15B2026-08-13
Geode Capital Management, LLC▲ Buy14,123,6892.75%$300.59M2026-08-12
Invesco Ltd.▼ Sell12,361,8812.40%$263.56M2026-08-14
Goldman Sachs Group Inc▲ Buy7,150,4621.39%$152.45M2026-08-14
Morgan Stanley▼ Sell6,359,7901.24%$135.59M2026-08-13
Bank of America Corp▲ Buy6,237,9501.21%$132.99M2026-08-14
Northern Trust Corp▲ Buy4,864,0040.95%$103.70M2026-08-13
Marshall Wace, LLP▲ Buy4,857,2670.94%$103.56M2026-08-13
Norges Bank▼ Sell4,144,9050.81%$88.37M2026-08-12
JPMorgan Chase & Co▼ Sell2,364,1390.46%$52.58M2026-08-12
AQR Capital Management LLC▲ Buy1,936,0130.38%$41.28M2026-08-14
Wells Fargo & Company▲ Buy1,029,4310.20%$21.95M2026-08-14
Artisan Partners Limited Partnership▼ Sell1,023,6770.20%$21.82M2026-08-13
Gotham Asset Management, LLC▲ Buy862,1230.17%$18.38M2026-08-14
Citigroup Inc▲ Buy667,7310.13%$14.24M2026-08-03
Verition Fund Management LLC▲ Buy464,2800.09%$9.90M2026-08-14
AllianceBernstein L.P.▲ Buy557,6800.11%$9.37M2026-08-14
Susquehanna International Group, LLP▼ Sell381,5530.07%$8.13M2026-08-14
Adage Capital Partners GP, L.L.C.▼ Sell288,3470.06%$6.15M2026-08-14
Man Group plc▲ Buy271,4650.05%$5.79M2026-08-14
Prudential Financial Inc▼ Sell245,4490.05%$5.23M2026-08-12
Neuberger Berman Group LLC▼ Sell245,4010.05%$5.23M2026-08-13
Citadel Advisors LLC▼ Sell222,7470.04%$4.75M2026-09-02
Q2 2026 flow:19.63M sh bought ($418.35M)9.89M sh sold ($211.17M)net +9.74M sh (+$207.18M)
Congressional Trading Activity
8 disclosed trades · ~$64.0K est. traded value · 4 buys, 4 sells
MemberChamberStateTypeAmountTradedFiled
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-312025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-09-252025-10-22
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-08-042025-09-12
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-222025-08-13
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-06-09
Dan SullivanSenateAK▼ Sell$1K - $15K2022-11-302023-07-26